The impact of statin use on the efficacy of abiraterone acetate in patients with castration ‐resistant prostate cancer

ConclusionsContrary to our initial hypothesis, there was a trend toward longer (rather than shorter) AA duration in statin users in the entire DFCI cohort and in the enzalutamide‐ and docetaxel‐naïve JHU patients. Together, these results do not support the hypothesis that statins interfere with AA efficacy.

Source: The Prostate - August 1, 2017 Category: Urology & Nephrology Authors: Lauren C. Harshman, Lillian Werner, Abhishek Tripathi, Xiaodong Wang, Benjamin L. Maughan, Emmanuel S. Antonarakis, Mari Nakabayashi, Rana McKay, Mark Pomerantz, Lorelei A. Mucci, Mary ‐Ellen Taplin, Christopher J. Sweeney, Gwo‐Shu Mary Lee, Philip W. Tags: ORIGINAL ARTICLE Source Type: research